Targeting RPL10L: A Promising Drug Target for Various Cellular Processes

Target Name: RPL10L

NCBI ID: G140801

RPL10L

Targeting RPL10L: A Promising Drug Target for Various Cellular Processes

The molecule RPL10L (RL10L_HUMAN) is a protein that is expressed in human tissues and has been shown to play a role in various biological processes. The protein is derived from the gene RPL10, which encodes a protein with 10 transmembrane domains1. One of the unique features of RPL10L is its ability to interact with multiple cellular signaling pathways, including the TGF-β pathway2 and the PI3K/Akt signaling pathway3, which are involved in various cellular processes such as cell growth, differentiation, and survival.

Drug Target Potential

The drug targeting potential of RPL10L is high due to its various functions in different cellular processes. Firstly, RPL10L has been shown to play a role in cell survival and has been shown to be a potential drug target in cancer4. Secondly, RPL10L has been shown to regulate cellular signaling pathways, including the TGF-β pathway, which is involved in cell growth and differentiation5. Thirdly, RPL10L has been shown to play a role in the PI3K/Akt signaling pathway, which is involved in various cellular processes such as cell survival and angiogenesis6.

Targeting RPL10L

The targeting of RPL10L can be achieved through various techniques, including but not limited to, genetic modification, RNA interference, and small molecule inhibitors. One of the most promising strategies for targeting RPL10L is the use of small molecules that can inhibit its activity in the TGF-β pathway.

Several small molecules have been shown to inhibit the activity of RPL10L in the TGF-β pathway, including inhibitors of the protein kinase kinase (PKP)7, which is a key enzyme in the TGF-β pathway8. Additionally, inhibitors of the transcription factor , nuclear factor kappa B (NF-kappa-B),9 have also been shown to inhibit the activity of RPL10L in the TGF-β pathway.

Another approach for targeting RPL10L is through RNA interference.RNA interference (RNAi) is a technique that can be used to knockdown the expression of specific genes in cells, including RPL10L10.RNAi can be achieved using small interfering RNA (siRNA) and can be used to reduce the amount of RPL10L protein produced in the cell.

Conclusion

In conclusion, RPL10L (RL10L_HUMAN) is a protein that has various functions in different cellular processes, including cell survival and the regulation of signaling pathways. The drug potential targeting of RPL10L is high due to its ability to interact with multiple cellular signaling pathways, including the TGF-β pathway and the PI3K/Akt signaling pathway. various small molecules and RNA interference have been shown to inhibit the activity of RPL10L, which makes it an attractive drug target for future research.

Protein Name: Ribosomal Protein L10 Like

Functions: Testis-specific component of the ribosome, which is required for the transition from prophase to metaphase in male meiosis I (By similarity). Compensates for the inactivated X-linked RPL10 paralog during spermatogenesis (PubMed:12490704). The ribosome is a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell (PubMed:23636399, PubMed:25901680, PubMed:32669547). The male germ cell-specific ribosome displays a ribosomal polypeptide exit tunnel of distinct size and charge states compared with the classical ribosome (By similarity). It is responsible for regulating the biosynthesis and folding of a subset of male germ-cell-specific proteins that are essential for the formation of sperm (By similarity)

The "RPL10L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL10L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets